Lorier Marianela, Magallanes Laura, Ibarra Manuel, Guevara Natalia, Vázquez Marta, Fagiolino Pietro
Department of Pharmaceutical Sciences, Faculty of Chemistry, Universidad de la República, P. O. Box 1157, 11800, Montevideo, Uruguay.
Bioavailability and Bioequivalence Centre for Medicine Evaluation, Universidad de la República, P. O. Box 1157, 11800, Montevideo, Uruguay.
Eur J Drug Metab Pharmacokinet. 2016 Dec;41(6):787-793. doi: 10.1007/s13318-015-0313-2.
Ketoprofen, a potent nonsteroidal anti-inflammatory drug, is clinically administered as a racemic mixture. One of the possible metabolism routes of ketoprofen is the inversion of the R- to S-enantiomer in the gastrointestinal tract. Ketoprofen, as a weak acid drug, might undergo recirculation through pancreatic/intestinal juices. The aim of the work was to investigate if a plasma-gastrointestinal tract recirculation of ketoprofen could explain its R-to-S chiral inversion after the oral administration of two modified-release formulations: a gastro-resistant delayed-release tablet (Reference) and an extended-release-plus-immediate-release bilayer tablet (Test).
Sixteen healthy Caucasian volunteers (eight women and eight men) participated in a ketoprofen bioequivalence study. Both formulations were administered with and without food. In both cases, standard meals were given throughout the experiment. R- and S-enantiomers were measured separately using a validated HPLC-UV chiral method. Mean concentration-time profiles of ketoprofen enantiomers in plasma were obtained for men and women. Area under the plasma concentration-time curve, maximum ketoprofen plasma concentration, and time-to-peak were also computed for both isomers, both modes of administration, and both sexes. S/R concentration ratio was assessed as an indicator of enantiomer chiral inversion rate.
Differences in the pharmacokinetics of S- and R-ketoprofen enantiomers were found after the Test administration. S-Ketoprofen presented a lower plasma exposure compared to R-enantiomer. However, the S/R concentration ratio increased 1 h (in men) and 2 h (in women) after meal intakes. This was related to pancreatic and/or intestinal and/or biliary secretions of the drug, followed by reabsorption and conversion of the R- to the S-isomer. The lower intestinal pH reported for men would lead to a higher oral bioavailability of the Test formulation and a higher reabsorption of both ketoprofen isomers in this sex. Hence, a higher rise of the S/R concentration ratio could be observed in men. No significant differences between isomers exposure were detected in both sexes after the Reference administration. Different lag times were observed after fed and fasting administration of this formulation; however, drug absorption coincided with food ingestion. Then, drug recirculation affected the S/R ratio from the beginning of drug exposure, minimizing the difference between isomers disposition.
R-to-S conversion rate could be mainly associated with several passages of the drug through the intestinal mucosa. The concentration-time profiles of ketoprofen in plasma after the administration of both formulations evidenced R-to-S conversion of recirculating drug following meal intakes.
酮洛芬是一种强效非甾体抗炎药,临床上以消旋体混合物形式给药。酮洛芬可能的代谢途径之一是在胃肠道中R - 对映体转化为S - 对映体。酮洛芬作为一种弱酸药物,可能通过胰液/肠液进行再循环。本研究的目的是探讨口服两种缓释制剂(一种胃内滞留缓释片(参比制剂)和一种缓释加速释双层片(受试制剂))后,酮洛芬的血浆 - 胃肠道再循环是否能解释其R - 到S的手性转化。
16名健康的白种人志愿者(8名女性和8名男性)参与了酮洛芬生物等效性研究。两种制剂均在进食和未进食情况下给药。在这两种情况下,整个实验过程中均给予标准餐。使用经过验证的HPLC - UV手性方法分别测定R - 和S - 对映体。获得了男性和女性血浆中酮洛芬对映体的平均浓度 - 时间曲线。还计算了两种异构体、两种给药方式和两性的血浆浓度 - 时间曲线下面积、酮洛芬的最大血浆浓度以及达峰时间。评估S/R浓度比作为对映体手性转化速率的指标。
受试制剂给药后,S - 和R - 酮洛芬对映体的药代动力学存在差异。与R - 对映体相比,S - 酮洛芬的血浆暴露量较低。然而,进食后1小时(男性)和2小时(女性)S/R浓度比增加。这与药物的胰腺和/或肠道和/或胆汁分泌有关,随后是R - 异构体重吸收并转化为S - 异构体。男性较低的肠道pH值会导致受试制剂更高的口服生物利用度以及该性别中两种酮洛芬异构体更高的重吸收。因此,在男性中可以观察到S/R浓度比有更高的升高。参比制剂给药后,两性中异构体暴露量均未检测到显著差异。该制剂在进食和空腹给药后观察到不同的延迟时间;然而,药物吸收与食物摄入同时发生。然后,药物再循环从药物暴露开始就影响S/R比,使异构体处置之间的差异最小化。
R - 到S的转化率可能主要与药物通过肠黏膜的多次转运有关。两种制剂给药后血浆中酮洛芬的浓度 - 时间曲线表明进食后再循环药物发生了R - 到S的转化。